弥漫性大B细胞淋巴瘤中Bcl-2抑制：“时代正在改变”？ - Suppr

Suppr

超能文献

Bcl-2 inhibition in DLBCL: "the times they are a-changing"?

作者信息

Vitolo Umberto, Novo Mattia

机构信息

Candiolo Cancer Institute, FPO-IRCCS.

出版信息

Blood. 2021 Feb 4;137(5):577-579. doi: 10.1182/blood.2020008924.

DOI:10.1182/blood.2020008924

PMID:33538802

Abstract

摘要

相似文献

Bcl-2 inhibition in DLBCL: "the times they are a-changing"?弥漫性大B细胞淋巴瘤中Bcl-2抑制：“时代正在改变”？

Blood. 2021 Feb 4;137(5):577-579. doi: 10.1182/blood.2020008924.

Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.ABT-199（GDC-0199）用于复发/难治性非霍奇金淋巴瘤患者的I期研究：在较高队列剂量下弥漫性大B细胞淋巴瘤（DLBCL）和滤泡性淋巴瘤（FL）中的观察到的反应。

Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):18-9.

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.CHOP 治疗弥漫性大 B 细胞淋巴瘤时抗凋亡 BCL-2 家族蛋白依赖性的异质性模式。

Int J Mol Sci. 2019 Nov 30;20(23):6036. doi: 10.3390/ijms20236036.

Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.使用ABT-199和高三尖杉酯碱靶向BCL2家族蛋白揭示弥漫性大B细胞淋巴瘤中依赖BCL2和MCL1的亚组

Clin Cancer Res. 2016 Mar 1;22(5):1138-49. doi: 10.1158/1078-0432.CCR-15-1191. Epub 2015 Oct 14.

Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.抑制 SYK 或 BTK 可增强 SHP1 阴性/BCL-2 阳性弥漫性大 B 细胞淋巴瘤对 venetoclax 的敏感性。

Leukemia. 2019 Oct;33(10):2416-2428. doi: 10.1038/s41375-019-0442-8. Epub 2019 Mar 14.

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.PI3Kα/δ 的靶向抑制与 BCL-2 阻断在基因定义的 DLBCL 亚型中具有协同作用。

Blood. 2019 Jan 3;133(1):70-80. doi: 10.1182/blood-2018-08-872465. Epub 2018 Oct 15.

Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.Voruciclib，一种临床阶段的口服 CDK9 抑制剂，可抑制 MCL-1 并使高危弥漫性大 B 细胞淋巴瘤对 BCL2 抑制敏感。

Sci Rep. 2017 Dec 21;7(1):18007. doi: 10.1038/s41598-017-18368-w.

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.靶向策略克服侵袭性 B 细胞淋巴瘤中 Venetoclax 的耐药性

Clin Cancer Res. 2018 Aug 15;24(16):3967-3980. doi: 10.1158/1078-0432.CCR-17-3004. Epub 2018 Apr 17.

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.ABT-199抑制BCL2并联合MCL1的药理学缺失对高危弥漫性大B细胞淋巴瘤细胞凋亡的协同诱导作用

Leukemia. 2015 Aug;29(8):1702-12. doi: 10.1038/leu.2015.99. Epub 2015 Apr 17.

Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.伊布替尼和 ABT-199 联合治疗弥漫性大 B 细胞淋巴瘤和滤泡性淋巴瘤。

Mol Cancer Ther. 2017 Jul;16(7):1246-1256. doi: 10.1158/1535-7163.MCT-16-0555. Epub 2017 Apr 20.

引用本文的文献

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤的靶向治疗和免疫治疗

Cancers (Basel). 2025 Jul 30;17(15):2517. doi: 10.3390/cancers17152517.

Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1.鲁帕他定抑制 OTUD3 通过去泛素化 MYL12A 和 PD-L1 促进弥漫性大 B 细胞淋巴瘤的进展和免疫逃逸。

Cell Death Dis. 2024 Aug 3;15(8):561. doi: 10.1038/s41419-024-06941-x.

Combined multiomics analysis reveals the mechanism of CENPF overexpression-mediated immune dysfunction in diffuse large B-cell lymphoma .联合多组学分析揭示了CENPF过表达介导的弥漫性大B细胞淋巴瘤免疫功能障碍的机制。

Front Genet. 2022 Dec 30;13:1072689. doi: 10.3389/fgene.2022.1072689. eCollection 2022.

Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression.酰基甘油激酶抑制通过上调 FOXO1 介导的 BCL-2 表达使 DLBCL 对 venetoclax 敏感。

Theranostics. 2022 Jul 18;12(12):5537-5550. doi: 10.7150/thno.72786. eCollection 2022.

High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients.ETV6高水平支持侵袭性B淋巴瘤细胞存活并预示弥漫性大B细胞淋巴瘤患者预后不良。

Cancers (Basel). 2022 Jan 11;14(2):338. doi: 10.3390/cancers14020338.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验